The Life Improvement Trial (LIFT)
The Life Improvement Trial (LIFT) aims to investigate two drugs, separately and in combination, Pyridostigmine (commonly known as Mestinon) and Low-Dose Naltrexone (LDN), for efficacy and to research the difference between responders and non-responders.
Skeletal Muscle Dysfunction
This project aims to explore the biological changes that occur in the muscles during Post-exertional Malaise (PEM).
Investigation into Post-Exertional Malaise Between Historical and Recent ME/CFS
The study expands on a previously-awarded proposal to thoroughly explore the underlying pathophysiology of post exertional malaise (PEM), the hallmark symptom of ME/CFS.
Sleep Disturbance in ME/CFS
Sleep Disturbance in ME/CFS Study AIM We intend to examine multiple sleep studies that have been conducted in the past two years and performed at the MGH Neurology Sleep Medicine Laboratory in well characterized patients with ME/CFS. LEAD INVESTIGATORS Wenzhong Xiao, PhD Janet Mullington, PhD Donna Felsenstein, MD Updates and Potential IRB approval received for […]
Mestinon Clinical Trial
This clinical trial will test the exercise response to Mestinon in people with ME/CFS.
Multi-omics Exercise Intolerance
This project aims to understand the origin of postural orthostatic tachycardia syndrome (POTS).
Heart Preload Failure
This study aims to evaluate different explanations of preload failure in ME/CFS patients.
Personalized Automated Symptom Summary (PASS)
Researchers are developing a tool to help clinicians more efficiently define the character and priorities of a patient’s current symptoms of ME/CFS, Post-Treatment Lyme Disease, or Fibromyalgia.